Kraš D.D.

Kraš D.D. company information, Employees & Contact Information

Explore related pages

Related company profiles:

For a century, generations of consumers have enjoyed a wide range of sweet Kraš products. Right from the start of production in 1911 till nowadays, Kraš has been systematically extending its production of all three confectionery categories – cocoa products, biscuits and wafers, as well as sugar confectionery. A long-time focus on manufacturing original products of high quality and satisfying customer needs and wants has ensured that Kraš has maintained its leading position among the confectioners of the region. Kraš flagship brands such as Bajadera, Griotte Desserts, Dorina chocolate, Animal Kingdom, Domaćica, Napolitanke wafers, Kiki and Bronhi toffees, and many others that are well-known to our consumers are the best proof of that. The complete manufacturing process is set up in accordance with the international confectionery standards and, in doing so the most stringent quality requirements have been met. Kraš today operates as a modern, market-oriented company with an annual output exceeding 33,000 tons of confectionery. More than half of total output is marketed domestically, while the remainder is being successfully exported to world markets.

Company Details

Employees
288
Founded
-
Address
Ravnice 48, Zagreb,10000,croatia
Phone
+385 1 2396 111
Email
in****@****kras.hr
Industry
Food And Beverage Manufacturing
NAICS
Food Manufacturing
Grain and Oilseed Milling
Other Food Manufacturing
Flour Milling and Malt Manufacturing
Starch and Vegetable Fats and Oils Manufacturing
Breakfast Cereal Manufacturing
Snack Food Manufacturing
Coffee and Tea Manufacturing
Flavoring Syrup and Concentrate Manufacturing
Seasoning and Dressing Manufacturing
All Other Food Manufacturing
Flour Milling
Rice Milling
Malt Manufacturing
Wet Corn Milling
Soybean and Other Oilseed Processing
Fats and Oils Refining and Blending
Roasted Nuts and Peanut Butter Manufacturing
Other Snack Food Manufacturing
Mayonnaise, Dressing, and Other Prepared Sauce Manufacturing
Spice and Extract Manufacturing
Perishable Prepared Food Manufacturing
All Other Miscellaneous Food Manufacturing
Website
kras.hr
HQ
Zagreb
Looking for a particular Kraš D.D. employee's phone or email?

Kraš D.d. Questions

News

KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma - Journal of Hematology & Oncology

KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma Journal of Hematology & Oncology

KRAS G12D vs G12C NSCLC: Immunotherapy Response Differs - Physician's Weekly

KRAS G12D vs G12C NSCLC: Immunotherapy Response Differs Physician's Weekly

Effect of KRAS Mutation Status on Treatment Outcomes in Metastatic Pancreatic Adenocarcinoma - The ASCO Post

Effect of KRAS Mutation Status on Treatment Outcomes in Metastatic Pancreatic Adenocarcinoma The ASCO Post

High Molecular Risk Mutations Assessed for Prognostic Scoring Systems for Primary Myelofibrosis - Hematology Advisor

High Molecular Risk Mutations Assessed for Prognostic Scoring Systems for Primary Myelofibrosis Hematology Advisor

Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis - Nature

Molecular characterization and prognostic implications of KRAS mutations in pancreatic cancer patients: insights from multi-cohort analysis Nature

New Horizons in KRAS -Mutant Lung Cancer: Dawn After Darkness - Frontiers

New Horizons in KRAS -Mutant Lung Cancer: Dawn After Darkness Frontiers

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer - ScienceDirect.com

Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer ScienceDirect.com

KRAS/BRAF Testing May Help Define Stage III Colon Cancer Prognosis - CancerNetwork

KRAS/BRAF Testing May Help Define Stage III Colon Cancer Prognosis CancerNetwork

Sotorasib Provides Consistent Clinical Benefit Over Docetaxel in Key Co-Alteration Subgroups of KRAS G12C+ NSCLC - OncLive

Sotorasib Provides Consistent Clinical Benefit Over Docetaxel in Key Co-Alteration Subgroups of KRAS G12C+ NSCLC OncLive

KRAS Mutations in Metastatic CRC Predict Survival Benefit of Chemo Combo - MedPage Today

KRAS Mutations in Metastatic CRC Predict Survival Benefit of Chemo Combo MedPage Today

HR+ NSCLC More Common in Women; EGFR, KRAS More Common in HR+ NSCLC - The American Journal of Managed Care® (AJMC®)

HR+ NSCLC More Common in Women; EGFR, KRAS More Common in HR+ NSCLC The American Journal of Managed Care® (AJMC®)

KRAS and PI3K Pathway Alterations Affect Survival in Patients With Pancreatic Cancer - Cancer Therapy Advisor

KRAS and PI3K Pathway Alterations Affect Survival in Patients With Pancreatic Cancer Cancer Therapy Advisor

The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis - Cancer Cell International

The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis Cancer Cell International

High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations - Frontiers

High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations Frontiers

UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma - Nature

UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma Nature

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy - ScienceDirect.com

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy ScienceDirect.com

Pembrolizumab Shows Survival Benefit in KRAS-Mutant NSCLC - MedPage Today

Pembrolizumab Shows Survival Benefit in KRAS-Mutant NSCLC MedPage Today

Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer - Molecular Cancer

Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer Molecular Cancer

Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma - Nature

Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma Nature

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism - ScienceDirect.com

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism ScienceDirect.com

Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer - medRxiv

Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer medRxiv

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation - ScienceDirect.com

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation ScienceDirect.com

Tumor Genomic Profile Is Associated With Arterial Thromboembolism Risk in Patients With Solid Cancer - JACC Journals

Tumor Genomic Profile Is Associated With Arterial Thromboembolism Risk in Patients With Solid Cancer JACC Journals

Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non-squamous non-small cell lung cancer patients - Wiley Online Library

Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non-squamous non-small cell lung cancer patients Wiley Online Library

Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the AR - Nature

Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the AR Nature

Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection - Frontiers

Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection Frontiers

A Comparative Analysis of Individual RAS Mutations in Cancer Biology - Frontiers

A Comparative Analysis of Individual RAS Mutations in Cancer Biology Frontiers

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab - Frontiers

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab Frontiers

The KRAS-G12C inhibitor: activity and resistance - Nature

The KRAS-G12C inhibitor: activity and resistance Nature

In vivo screening identifies GATAD2B as a metastasis driver in KRAS -driven lung cancer - Nature

In vivo screening identifies GATAD2B as a metastasis driver in KRAS -driven lung cancer Nature

Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study - ScienceDirect.com

Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study ScienceDirect.com

Co-occurring genomic alterations and immunotherapy efficacy in NSCLC - Nature

Co-occurring genomic alterations and immunotherapy efficacy in NSCLC Nature

Genomic Profiling Identifies Somatic Mutations Predicting Thromboembolic Risk in Patients with Solid Tumors - medRxiv

Genomic Profiling Identifies Somatic Mutations Predicting Thromboembolic Risk in Patients with Solid Tumors medRxiv

Pembrolizumab in KRAS -Mutant and Wild-Type PD-L1–Positive Nonsquamous NSCLC - The ASCO Post

Pembrolizumab in KRAS -Mutant and Wild-Type PD-L1–Positive Nonsquamous NSCLC The ASCO Post

Kras and Studio Sonda Win Prestigious Award for Dorina Redesign - Total Croatia

Kras and Studio Sonda Win Prestigious Award for Dorina Redesign Total Croatia

Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1, an ancillary of JCOG0910 - Wiley Online Library

Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1, an ancillary of JCOG0910 Wiley Online Library

Mutation frequency and copy number alterations determine prognosis and metastatic tropism in 60,000 clinical cancer samples - medRxiv

Mutation frequency and copy number alterations determine prognosis and metastatic tropism in 60,000 clinical cancer samples medRxiv

Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1 - PNAS

Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1 PNAS

LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER - PR Newswire

LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER PR Newswire

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition - The Lancet

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition The Lancet

(PDF) Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients - researchgate.net

(PDF) Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients researchgate.net

Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes - Nature

Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes Nature

Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer - Nature

Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer Nature

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases - Nature

Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases Nature

Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controls - Wiley Online Library

Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controls Wiley Online Library

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients | Blood Cancer Journal - Nature

Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients | Blood Cancer Journal Nature

Much Loved Brand Kras Creates Chocolate with Croatian Cvarci - Total Croatia

Much Loved Brand Kras Creates Chocolate with Croatian Cvarci Total Croatia

RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas | British Journal of Cancer - Nature

RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas | British Journal of Cancer Nature

Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug? - Dove Medical Press

Evolution of regorafenib from bench to bedside in colorectal cancer: Is it an attractive option or merely a “me too” drug? Dove Medical Press

Top Kraš D.D. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant